文献速递特殊人群用药

Bamlanivimab与Etesevimab在轻中度COVID-19患者中的群体药代动力学与药效学

Population Pharmacokinetics and Pharmacodynamics of the Neutralizing Antibodies Bamlanivimab and Etesevimab in Patients With Mild to Moderate COVID-19 Infection.
PubMed 文献 · Clin Pharmacol Ther · 2021-09-24

本研究基于2项II期临床试验共2,970例轻中度COVID-19患者的数据,建立药代动力学/药效学(PK/PD)模型刻画病毒载量时间过程。模型估算bamlanivimab和etesevimab的血清IC90分别为4.2 µg/mL和12.6 µg/mL,700 mg bamlanivimab联合1,400 mg etesevimab可使病毒载量降至最大程度,更高剂量无额外效应。年龄、性别、种族、基线病毒载量和肝损伤对PK无显著影响,不建议剂量调整;症状出现后越早给药病毒载量下降越大。

要点

  • 700 mg bamlanivimab联合1,400 mg etesevimab达到最大病毒载量下降,更高剂量无额外获益。
  • 年龄、性别、种族、基线病毒载量和肝损伤不影响抗体PK,无需剂量调整。
  • 症状出现后越早给药病毒载量下降越大,7天内相对安慰剂典型下降80%或93%。

核心结论

  • 700 mg bamlanivimab联合1,400 mg etesevimab可最大程度降低病毒载量,更高剂量无额外效应。
  • 年龄、性别、种族、基线病毒载量和肝损伤对两种抗体PK无显著影响,不建议剂量调整。
  • 症状出现后越早给药病毒载量下降越大,强调尽早治疗的重要性。

研究设计与样本

  • 基于2项II期临床试验共2,970例轻中度COVID-19患者数据建立PK/PD模型。
  • 模型用于识别使至少90%患者达到血清药物浓度≥IC90并维持至少28天的最佳剂量。

主要发现

  • bamlanivimab血清IC90(95%CI)为4.2(3.2-4.3)µg/mL。
  • etesevimab血清IC90(95%CI)为12.6(9.7-12.8)µg/mL。
  • 临床试验数据证实700 mg bamlanivimab和1,400 mg etesevimab病毒载量降幅最大,更高剂量无额外效应。
  • 相对安慰剂,7天内病毒载量典型下降80%(症状出现后4天给药)或93%(症状出现后1天给药),P < 0.0001。

关键数值与推荐

  • bamlanivimab目标血清浓度为IC90 4.2 µg/mL(95%CI 3.2-4.3)。
  • etesevimab目标血清浓度为IC90 12.6 µg/mL(95%CI 9.7-12.8)。
  • 推荐剂量为700 mg bamlanivimab联合1,400 mg etesevimab。

临床怎么用

  • 轻中度COVID-19早期患者可使用700 mg bamlanivimab联合1,400 mg etesevimab治疗。
  • 无需根据年龄、性别、种族、基线病毒载量或肝损伤调整剂量。
  • 应在症状出现后尽早给药以获得更大病毒载量下降。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bamlanivimab and etesevimab are neutralizing antibodies indicated for treatment of coronavirus disease 2019 (COVID-19) in patients with early mild or moderate disease. We present the use of pharmacokinetic/pharmacodynamic (PK/PD) modeling that characterizes the timecourse of viral load obtained from 2,970 patients from 2 phase II clinical trials. The model was used for identification of optimal doses that would result in at least 90% of patients achieving serum drug concentrations that result in 90% of maximum drug effect (IC90) for at least 28 days. The serum IC90 (95% confidence interval) was estimated to be 4.2 (3.2-4.3) µg/mL for bamlanivimab and 12.6 (9.7-12.8) µg/mL for etesevimab. Observed clinical trial data confirmed PK and PK/PD model predictions that doses of 700 mg bamlanivimab and 1,400 mg etesevimab would result in maximum reduction in viral load, with no additional effect seen at higher doses. No dose adjustment is recommended as age, sex, race, baseline viral load, and hepatic impairment did not have a significant impact on the PK of the antibodies. Earlier drug administration resulted in greater reductions in viral load, demonstrating the importance of receiving treatment as soon as possible. Relative to placebo, typical reduction in viral load over a 7-day period was estimated to be 80 or 93% (drug administered 4 days or 1 day after the onset of symptoms, respectively), P < 0.0001. PK/PD modeling and simulation was pivotal throughout the drug development and emergency use authorization process.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Chigutsa E, O'Brien L, Ferguson-Sells L, et al. Population Pharmacokinetics and Pharmacodynamics of the Neutralizing Antibodies Bamlanivimab and Etesevimab in Patients With Mild to Moderate COVID-19 Infection. Clin Pharmacol Ther. 2021. PMID: 34514598. doi:10.1002/cpt.2420

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。